CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 InflammationBenzinga • 01/31/22
Regeneron, Sanofi withdraw application for Libtaya as a cervical cancer treatment in the U.S.Market Watch • 01/28/22
Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised)Zacks Investment Research • 01/21/22
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin DiseaseBenzinga • 01/19/22
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's DiseasePRNewsWire • 01/11/22
Sanofi (SNY) CEO Paul Hudson Presents at JPMorgan 40th Annual Healthcare Conference (Transcript)Seeking Alpha • 01/11/22
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicinesGlobeNewsWire • 01/07/22
Sanofi Expects Q4 FY21 Vaccine Sales Lower Than Year-Ago, Positive Currency ImpactBenzinga • 01/04/22
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated BiologicsGlobeNewsWire • 12/21/21
Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of SanofiGlobeNewsWire • 12/16/21